AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Tourmaline Bio, Inc. Director's Dealing 2021

May 7, 2021

32658_dirs_2021-05-06_cc711a9c-9629-493d-bb5a-45c7ea25ebea.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Talaris Therapeutics, Inc. (TALS)
CIK: 0001827506
Period of Report: 2021-05-06

Reporting Person: Zdanowski Michael (Chief Technology Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$5.72	2030-10-02	Common Stock (224298)		Direct

Footnotes

F1: The shares underlying this option shall vest as follows: 25% shall vest on October 26, 2021; and the remaining shall vest in 36 equal monthly installments thereafter.